A method for evaluating enzyme performance and function has been developed and a national invention patent has been applied for; the developed related enzymes have been applied to the company's product series.
Direct PCR amplification of blood/blood card; multiplex amplification; The probe-based qPCR product line covers conventional, high-sensitivity, multiplex probes, ARMS, methylation, multi-color probe melting curves, etc.
We develop nucleic acid extraction reagents based on the magnetic bead/membrane column method for nucleic acid extraction, which currently covers samples such as whole blood DNA, plasma cfDNA, FFPE DNA, Escherichia coli plasmid, animal/plant tissue DNA and RNA.
We develop products such as library sample fragment size screening, library concentration determination, and ribosomal RNA removal based on NGS high-throughput sequencing. Customers can independently select the sample fragment size according to their sequencing needs.
Beijing Qihengxing Biotechnology Co., Ltd. was established in 2018. It is a national high-tech enterprise with many invention patents. Relying on core technology platforms such as enzyme engineering platform, PCR/qPCR system platform, nucleic acid extraction platform, NGS platform with independent intellectual property rights, the company has developed many high-quality products in multiple application directions such as molecular biology, NGS application, and synthetic biology, and has built a technology/practical training and product customization development service platform based on the integration of industry, academia and research.
